sorafenib has been researched along with Experimental Neoplasms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, Y; Lu, X; Tang, W; Wu, J; Xin, BT; Zhang, Y; Zheng, Y; Zhou, X | 1 |
| Chen, Y; Gu, Y; Han, W; Lu, T; Qian, W; Tang, W; Yang, W; Zhang, F; Zhou, X | 1 |
| Chao, YS; Chen, CH; Chen, CP; Chen, CT; Chou, LH; Hsu, JT; Hsu, T; Huang, CL; Huang, YL; Jiaang, WT; Kuo, PC; Lin, WH; Liu, HE; Lu, CT; Song, JS; Yeh, TK; Yen, KJ; Yen, SC | 1 |
| Cao, YX; He, YY; Mao, S; Xiao, X; Xie, XX; Xin, MH; Xuan, W; Zhang, S; Zhang, SQ; Zuo, SJ | 1 |
| Di, D; Han, Y; Li, R; Li, W; Liu, J; Xin, A; Yan, Q; Zhang, Y | 1 |
| Chen, K; Huang, SZ; Jiang, XJ; Li, LL; Li, WM; Li, YS; Luo, YF; Wang, YL; Wei, YQ; Xiang, R; Yan, HX; Yang, J; Yang, QY; Yang, SY; Yang, W; Zhang, G; Zhu, JQ | 1 |
| Deng, Y; Dong, S; Han, W; Han, Y; Li, Z; Liu, S; Luo, Z; Ni, D; Niu, L; Pi, R; Song, L; Sun, D; Wei, Q; Zhao, Y; Zhu, T | 1 |
| Chen, B; Dai, R; Feng, M; Li, M; Liu, J; Tang, J; Xiao, S; Zhang, X | 1 |
| Cai, Y; Cao, Z; Han, W; Lu, M; Ran, J; Song, C; Tang, C; Wei, Z; Zhang, G; Zou, H | 1 |
| Jiang, W; Li, L; Lian, ZX; Liu, QZ; Long, J; Wang, YC; Yan, K; Yang, JB; Zhao, YY; Zhao, ZB | 1 |
| Alba, G; Carlson, T; Chen, A; Coberly, S; Dai, K; Eksterowicz, J; Hollenback, D; Huard, J; Kamb, A; Keegan, K; Li, C; Li, Z; Liang, L; Liu, L; Lo, MC; Ma, J; McGee, LR; Medina, J; Ngo, R; Orf, J; Quéva, C; Ragains, M; Wang, X; Weidner, M; Wickramasinghe, D; Zhao, S | 1 |
| Coplin, MA; Donahue, RN; Farsaci, B; Grenga, I; Hodge, JW; Lepone, LM; Molinolo, AA | 1 |
| De Velasco, MA; Hatanaka, Y; Kura, Y; Minami, T; Nishio, K; Nozawa, M; Oki, T; Ozeki, T; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshikawa, K; Yoshimura, K | 1 |
| Gao, M; Hua, H; Jiang, Y; Kong, Q; Luo, T; Wang, J; Yin, Y | 1 |
| Booth, L; Dent, P; Poklepovic, A; Roberts, JL | 1 |
| Bian, S; Cai, H; Cui, Y; Fan, Y; Liang, J; Sui, J; Sun, Y; Xu, Z; Zhang, X; Zhou, L | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Bouzin, C; Calderon, PB; Charette, N; Danhier, P; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J; Magat, J; Mignion, L; Sonveaux, P; Starkel, P; Verrax, J | 1 |
18 other study(ies) available for sorafenib and Experimental Neoplasms
| Article | Year |
|---|---|
Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Structure-Activity Relationship | 2015 |
Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
Topics: Amides; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Purines; Structure-Activity Relationship; Urea | 2015 |
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Point Mutation; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazoles | 2015 |
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
Topics: Amines; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Urea | 2016 |
Design, synthesis, and anticancer properties of isocorydine derivatives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aporphines; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship | 2017 |
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
Topics: Amines; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Structure; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Proto-Oncogene Proteins c-ret; Structure-Activity Relationship | 2018 |
Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Osteosarcoma; Pyridines; Structure-Activity Relationship; Thiazolidines | 2022 |
Multifunctional FeS
Topics: Animals; Cell Line, Tumor; Mice; Nanoparticles; Neoplasms, Experimental; Photochemotherapy; Photothermal Therapy; Serum Albumin, Bovine; Sorafenib | 2021 |
Novel NIR-II semiconducting molecule incorporating sorafenib for imaging guided synergetic cancer phototherapy and anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Drug Screening Assays, Antitumor; Humans; Infrared Rays; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms, Experimental; Optical Imaging; Photochemotherapy; Semiconductors; Sorafenib | 2021 |
Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Homeodomain Proteins; Immunity, Cellular; Lymphocytes; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Sorafenib | 2018 |
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Naphthyridines; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Vaccines, Synthetic | 2014 |
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Models, Animal; Everolimus; Genetic Engineering; Homozygote; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2015 |
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Glucans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Benzamides; Blotting, Western; Diphenylamine; Electron Spin Resonance Spectroscopy; Fibrosarcoma; Glutathione; Liver Neoplasms, Experimental; Mice; Neoplasms, Experimental; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Sorafenib | 2012 |